Introduction
For two decades chloramphenicol has been accepted as the drug of choice in the oral treatment of enteric fever (Robertson et al., 1968) . Nevertheless, its use in the treatment of enteric fever has many disadvantages. The number of days taken for the temperature to return to normal-defervescence-after starting treatment with chloramphenicol has been increasing progressively over the years-3-5 days in 1948 (Woodward et al., 1948) , 4-1 days in 1962 (Huckstep, 1962) , and 5-1 days in 1967 (Kamat et al., 1968) . Chakraborty (1961) noted that between 1956 and 1960 the average defervescence period after chloramphenicol increased from 3.5 to 6.2 days, showing a gradual yearly increase. The features of typhoid toxaemia such as headache, restlessness, lassitude, apathy, drowsiness, anorexia, mental disorientation, hyperexcitability or delirium, involuntary movements, and tachycardia sometimes persist even when the patient becomes afebrile. "Toxic crisis"-an apparently drug-induced exacerbation of toxaemia that sometimes occurs early in the course of treatment (Marmion, 1952 )-is an ever-present danger in treatment of enteric fever with chloramphenicol (Marmion, 1952; Kamat, 1969) .
In chloramphenicol-treated cases relapses are more common than in untreated cases (Huckstep, 1962) , and carriers remain unaffected (Cluff, 1963) . Chloramphenicol has been said to be the leading cause of drug-induced aplastic anaemia (New England 7ournal of Medicine, 1967) . Its leukaemogenic effects have now been recognized (Brauer and Dameshek, 1967) . These drawbacks of chloramphenicol therapy have led many workers in this field to look for safer and more effective remedies. Thus ampicillin (Sanders, 1965; Robertson et al., 1968) , niridazole (Kamat et al., 1968) , and furazolidone (Omar and Wahab, 1967; Kamat, 1968a) (Akinkugbe et al., 1968; Kamat, 1969; Kamat et al., 1969; Semprevivo et al., 1969) Out of a total of 900 cases of clinically suspected enteric fever, blood clot cultures were positive for salmonellae in 220 (Salmonella typhi in 212 and S. paratyphi A in 8). Only these-220 patients with bacteriologically proved enteric fever were studied-100 belonged to the group treated with trimethoprim-sulphamethoxazole and 120 formed the control group treated with chloramphenicol.
Patients were kept under observation in hospital for at least 15 days after defervescence. Owing to shortage of beds the stay in hospital of patients in the trial could not be extended. After treatment and before discharge from hospital clot culture was repeated in each case and stool culture for salmonellae was carried out.
After discharge patients are being followed up, and periodical clinical and bacteriological examinations will be made for one year. The results of this follow-up to determine relapses, long-term complications, long-term drug toxicity, and incidence of carrier rate after treatment with trimethoprimsulphamethoxazole and chloramphenicol will be reported later.
Dosage Schedules
Trimethoprim-Sulphamethoxazole.-Early in the trial the dose given was three tablets twice a day till defervescence, followed by two tablets twice a day for seven days. Chloramphenicol.-The routine hospital schedule was used -that is, 500 mg. six-hourly till defervescence followed by 500 mg. eight-hourly for four days, 500 mg. 12-hourly for four days, and 250 mg. eight-hourly for four days.
Clinical Details
The ages of the patients in the two treatment groups on admission are shown in Table I . The youngest and oldest were aged 12 and 65. The duration of fever before admission is shown in Table II . The longest and shortest durations of fever before institution of therapy with trimethoprimsulphamethoxazole were 15 and 2 days respectively and in the chloramphenicol-treated group 30 days and 1 day respectively. Toxaemia was present on admission in 17 of the 100 patients in the trimethoprim-sulphamethoxazole group and in 32 of the 120 in the chloramphenicol group. The temperature on admission is shown in Table III . The mean duration of f ever before admission was 6-6 days in the trimethoprimsulphametho azole grou p and 7 3 days in the chloramphenicol group. Response to Treatment.-In both groups the response to therapy was good and there were no treatment failures. The rapidity of response of fever to treatment in both groups was similar, average defervescence occurring in 4.0 days in the trimethoprim-sulphamethoxazole group and 4.3 days in the chloramphenicol group.. Response of toxaemia to treatment, however, was different in the two groups. All patients admitted with toxaemia in the trimethoprim-sulphamethoxazole group responded favourably, a daily improvement in toxaemia being noticeable and most of them (88%) were free of toxaemia within three days and all in four days. In comparison only 40% of patients admitted with toxaemia in the chloramphenicol group were free of toxaemia by the third day, the rest remaining toxaemic for up to seven days. This is statistically significant. No patient who was non-toxaemic on admission in the trimethoprim-sulphamethoxazole group developed toxaemia after starting treatment with this drug, while in the chloramphenicol group 11 patients who were non-toxaemic on admission developed toxaemia after starting treatment with chloramphenicol. This is highly significant (P<0.001).
Complications.-"Toxic crisis" did not occur in the trimethoprim-sulphamethoxazole group, but 10 patients in the chloramphenicol group developed "toxic crisis"; this is highly significant. Complications such as perforation and haemorrhage were not seen in either group during the period in hospital. The absence of haemorrhage and perforation in our series may surprise many workers from other parts of the world. These results however, were not surprising in Bombay as low complication rates are usual there (Kalra et. al., 1968; Padmanabhan, 1968; Kamat, 1968a Kamat, , 1968b Kamat, , 1969 Kamat et al., 1968 Kamat et al., , 1969 . Even in the prechloramphenicol era, enteric fever in South India had a low rate of perforation and mortality (Dunkerley, 1946) . Perhaps differences in strains of the invading organism, resistance of the host dependent on ethnic and geographical differences, and promptness of specific therapy after onset of symtZoms explain the differences in incidence of serious complications in different parts of the world.
Adverse Reactions.-Nausea, vomiting, diarrhoea, and insomnia were fairly common in both groups, the difference in the frequency of occurrence not being statistically significant. Since these are also symptoms of enteric fever itself it is difficult to determine whether they were caused by the disease or by the drug administered. Retention of urine occurred in two patients in the chloramphenicol group, but since enteric fever itself can cause this we cannot definitely say that chloramphenicol was responsible. Similarly, the occurrence of paraesthesiae, which was noted in one patient in the trimethoprim-sulphamethoxazole group, cannot be definitely ascribed to the drug.
The, incidence of "toxic crisis," appearance of toxaemii after starting treatmentj and glossitis in 10, 11, and 7 patients respectively in the chloramphenicol group, and the absence of these adverse reactions in the trimethoprimsulphamethoxazole group are highly significant. Pronounced weakness and even prostration were notable features in the chloramphenicol group, weakness often persisting for two to three weeks after completion of treatment. By comparison, in the trimethoprim-sulphamethoxazole group weakness was short-lived, lasting up to about a week after completion of therapy.
Blood urea, serum bilirubin, and peripheral blood pictures after oompletion of treatment with trimethoprimsulphamethoxazole in 10% of randomly chosen patients did not show abnormalities.
